BoNT-A

Phase 2Small molecule

SSir Run Run Shaw Hospital

BoNT-A is one of 16 small molecule programs targeting Premature Ejaculation. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Premature EjaculationActive, not recruiting

Traumatic Brain InjuryRecruiting

Premature EjaculationPreclinical

Active, not recruiting

Traumatic Brain InjuryPhase 2

Recruiting

Competition

Competitive Landscape

11 competitors in Premature Ejaculation

#DrugCompanyPhaseTrials

Viagra

VViatris Specialty LLC

Approved

1 2

Xylocaine

MMEDRx USA, Inc.

Approved

1 3

Botox

AbbVie

Phase 3

1 4

Standard Treatment

Boehringer Ingelheim

Phase 3

1 5

BoNT-A

SSir Run Run Shaw Hospital

Phase 2

1 6

BP1.4979

BBioprojet

Phase 2

1 7

Botox

RRevance Therapeutics, Inc.

Preclinical

1 8

Dapoxetine Hydrochloride

Johnson & Johnson

Preclinical

2 9

Serotonin Reuptake Inhibitor (SSRI)

MMedipol University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Traumatic Brain Injury

NCT06293300

Clinical

Trials by Indication[1]

Spasticity2 trials

The Effectiveness of Early Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults

Unknown status·SSir Run Run Shaw Hospital·Phase 4·NCT02505802·30 enrolled

Efficacy of Extracorporeal Shock Wave Therapy on Spasticity

Completed·KKayseri City Hospital·N/A·NCT06225024·40 enrolled

Migraine1 trial

"Follow the Sutures". A New Procedure for Injection of Botulinum Toxin for Chronic Migraine

Completed·NNorwegian University of Science and Technology·Phase 2·NCT03543254·20 enrolled

Premature Ejaculation1 trial

Dual-Site Botulinum Toxin Type A Injection for Lifelong Premature Ejaculation

Completed·—·N/A·NCT07426640·150 enrolled

Tremor1 trial

Kinematic-guided BoNT-A Treatment for ET and PD Tremor

Unknown status·WWestern University, Canada·Phase 2·NCT02427646·54 enrolled

Treatment1 trial

Study Comparing Treatment With Alluzience vs Reconstituted Toxin

Completed·GGalderma R&D·Phase 4·NCT05277337·150 enrolled

3 more indications

Overactive Bladder1 trial

Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome

Completed·—·Phase 2·NCT01657409·90 enrolled

Carpal Tunnel Syndrome1 trial

BotulInum Toxin Type A for Peripheral Neuropathic Pain in subjEcts With Carpal Tunnel Syndrome

Unknown status·FFrancesco Bono·Phase 2·NCT05411900·164 enrolled

Traumatic Brain Injury1 trial

Understanding and Treating TBI Associated Photophobia With Botulinum Toxin Type A and Its Impact on Visual Function

Recruiting·UUniversity of Miami·Phase 2·NCT06293300·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for BoNT-A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BoNT-A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BoNT-A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sir Run Run Shaw Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSir Run Run Shaw Hospital

BoNT-A

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Spasticity2 trials

Migraine1 trial

Premature Ejaculation1 trial

Tremor1 trial

Treatment1 trial

Overactive Bladder1 trial

Carpal Tunnel Syndrome1 trial

Traumatic Brain Injury1 trial

References

Drug Info

Quick Facts

Related News